Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK Settles Hundreds Of Avandia Suits Before FDA Advisory Cmte. Meeting

Executive Summary

The upcoming FDA advisory committee meeting on Avandia (rosiglitazone) may be putting pressure on GlaxoSmithKline to settle a chunk of the product liability suits facing the company

You may also be interested in...

Avandia's TIDE May Come In Smaller

Two advisory panels recommended that FDA allow the trial of GlaxoSmithKline's Avandia (rosiglitazone) to continue but questioned its design, providing important hints for drug companies planning post-marketing safety trials in the future.

Grassley And Baucus Turn Up Heat On GSK With Attack On Avandia Data Handling

Company's internal e-mails suggest GSK hid vital studies related to safety of Avandia relative to competitor, senators charge.

Avandia Committee Review: FDA Puts Five Options On Table For Advisory Panels

Advisors could recommend that GlaxoSmithKline's diabetes drug be taken off the market, that the warnings on its label be downgraded, or a range of in-between options.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts